Loading…
← CockpitCompetitor Analysis › 688767.SS Hangzhou Biotest Biotech Co., Ltd. Class AOpen in the cockpit ↗

Hangzhou Biotest Biotech Co., Ltd. Class A688767.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Medical Specialties
Momentum strong 70
Mkt cap
$878M
US dollars, full cap
Free float
100%
of shares outstanding
$/day
$9.98M
20-day average traded
Fwd P/E
37.0×
forward earnings
ROIC−WACC
-4.5 pp
WACC 7.0%
Hurdle
n/a
no reverse DCF
Next earnings
159 days
26 Apr 2027
Close · CNYCN¥36.72
1D-2.4%
1W-6.5%
1M-7.6%
3M-12.9%
6M-11.7%
YTD-2.8%
1Y-10.6%
ATR %5.0%
52w lowhigh28.0% off high

What Hangzhou Biotest Biotech does

Employees: 613

Hangzhou Biotest Biotech at a glance

Size Hangzhou Biotest Biotech (688767.SS) is a China Health Care company (Medical Specialties) with a market value of $878M, the 2414th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥36.72 on 18 Nov 2026.

Performance Over six months the shares fell 11.7%, against -15.1% for the median peer and -20.0% for the China market (cap-weighted) — 9th highest of 21 in its peer set.

Growth Revenue fell 4.5% over the last twelve months (peer median +7.3%); the operating margin is 3.2% (peer median 9.4%).

Valuation It trades at 37.0× forward earnings against a peer median of 24.1× (5th most expensive of 15).

Capital Return on invested capital runs 4.5 points below its cost of capital (7.0% WACC).

Next results Next results expected around 26 Apr 2027 (exchange calendar; dates can move).

Relative performance

809010021 May 202621 Aug 202618 Nov 2026688767.SS 88Peer median 85
Six months, rebased to 100: Hangzhou Biotest Biotech against the median of its 20 peers (local-currency closes).

Hangzhou Biotest Biotech financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥452MCN¥445MCN¥555MCN¥439MCN¥1.88B
Revenue growth—-20%+27%-77%—
Gross profitCN¥221MCN¥192MCN¥283MCN¥208MCN¥993M
EBITDAn/aCN¥35.5MCN¥135MCN¥33.1MCN¥776M
Net incomeCN¥10.3MCN¥49.3MCN¥170MCN¥107MCN¥774M
Free cash flow-CN¥43.3M-CN¥16.4M-CN¥108MCN¥78.8MCN¥539M
Capital expenditureCN¥139MCN¥130MCN¥245MCN¥56.4MCN¥179M
Total debtCN¥100MCN¥18.6MCN¥440,516CN¥3.04MCN¥7.64M

Quarterly statements and history in the cockpit →

Hangzhou Biotest Biotech competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-20%-10%0%688626688575688277301580002658BVS688656301602AORTKURN36006033671187KIDS2906507780688068MCAPAMS688767.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Hangzhou Biotest Biotech is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%0×200×400×688626688575301580002658BVS688656AORTKURN360060336711877780688767.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Hangzhou Biotest Biotech is the large dot.

Hangzhou Biotest Biotech competitors and peer comparison

How Hangzhou Biotest Biotech compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Hangzhou Biotest Biotech against its 20 peers (data as of 18 Nov 2026)
Measure688767.SSPeer medianRank in peer set
1-month return-7.6%-6.8%11th highest of 21
6-month return-11.7%-15.1%9th highest of 21
Distance from 52-week high-28.0%-43.3%6th highest of 21
Revenue growth (TTM)-4.5%+7.3%3rd lowest of 21
Operating margin3.2%9.4%4th lowest of 21
Forward P/E37.0×24.1×5th most expensive of 15
ROIC minus cost of capital-4.5 pp+1.5 pp6th lowest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Hangzhou Biotest Biotech 688767.SSChina$878M-12%-4%3%37.0×n/an/a
Xiangyu Medical 688626.SSChina$877M-38%0%4%56.2×n/an/a
Shenzhen YHLO Biotech 688575.SSChina$882M-16%+3%12%30.7×2.0%+12.7%
Tinavi Medical Technologies 688277.SSChina$872M-36%-2%-59%n/an/an/a
Aidite (Qinhuangdao) Technology 301580.SZChina$888M-12%+17%18%26.2×19.3%+23.3%
Beijing SDL Technology 002658.SZChina$864M-34%-13%9%22.4×16.8%+2.9%
Bioventus BVSUnited States$895M-3%+4%10%13.0×7.5%+12.1%
HOB Biotech 688656.SSChina$858M-33%+6%7%166.9×37.6%+12.4%
Shantou Institute of Ultrasonic Instruments 301602.SZChina$858M-25%+4%30%n/a11.1%+4.6%
Artivion AORTUnited States$905M-18%+14%5%383.6×n/an/a
Kuros Biosciences KURN.SWSwitzerland$907M-12%+41%6%70.5×n/an/a
Modern Dental 3600.HKHong Kong$844M+24%+12%22%8.5×-7.1%+11.3%
Cisen Pharmaceutical 603367.SSChina$843M-15%-6%8%7.9×-14.6%-1.3%
Cofoe Medical Technology 1187.HKHong Kong$836M-11%+40%10%13.1×-6.4%+6.6%
OrthoPediatrics KIDSUnited States$826M+71%+16%-8%n/an/an/a
Ningbo Jansen Superconducting Technologies 688805.SSChina$818M-36%+36%16%n/a35.6%+17.1%
L&C BIO 290650.KSSouth Korea$943M-37%+65%20%n/a32.6%+21.0%
Menicon 7780.TJapan$944M+26%+6%9%20.9×n/an/a
Beijing Hotgen Biotech 688068.SSChina$815M-37%+8%-94%n/an/an/a
MedCap MCAP.STSweden$811M-4%+17%15%25.8×2.7%+20.9%
Advanced Medical Solutions AMS.LUnited Kingdom$811M+27%+6%12%20.7×20.0%+21.4%

Questions

Which companies are Hangzhou Biotest Biotech's closest peers?
The cockpit's peer set: Xiangyu Medical (688626.SS), Shenzhen YHLO Biotech (688575.SS), Tinavi Medical Technologies (688277.SS), Aidite (Qinhuangdao) Technology (301580.SZ), Beijing SDL Technology (002658.SZ), Bioventus (BVS), HOB Biotech (688656.SS), Shantou Institute of Ultrasonic Instruments (301602.SZ).
Is Hangzhou Biotest Biotech expensive compared with its peers?
On forward p/e it trades at 37.0× against a peer median of 24.1×, 5th most expensive of 15 in its peer set.
How has Hangzhou Biotest Biotech stock performed?
Over six months to 18 Nov 2026 the shares returned -11.7% against -15.1% for the median peer; over one year -10.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.